Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells

Jiang,Li; Luo,Ruo-Yu; Yang,Jing; Cheng,Yan-Xiang

doi:10.3892/mmr.2012.1216

Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells

Authors:
- Li Jiang
- Ruo-Yu Luo
- Jing Yang
- Yan-Xiang Cheng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, P.R. China, Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, P.R. China, Reproductive Medical Center, Renmin Hospital of Wuhan University, Wuhan 430060, P.R. China
Published online on: December 3, 2012 https://doi.org/10.3892/mmr.2012.1216
Pages: 425-430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Survivin (SVV) is an important member of the inhibitor of apoptosis family. It is overexpressed in a number of cancer types, including human ovarian carcinomas. SVV promotes invasion, metastasis, growth and survival of malignant cells and confers resistance to specific chemotherapeutic drugs. The present study aimed to elucidate the role and possible mechanisms of SVV in cisplatin-resistant ovarian cancer cells (A2780/CP). Using a loss-of-function approach, we investigated the effects of adenovirus-mediated knockdown of SVV by small hairpin RNA (ad5-SVV) on the expression of pro-caspase-3, cleaved caspase-3, proliferating cell nuclear antigen (PCNA) and matrix metalloproteinase-2 (MMP-2) in A2780/CP cells by real-time PCR and western blot analysis. Proliferation was measured by MTT assay, invasive potential by Transwell, and cell apoptosis by FITC-Annexin V and propidium iodide for the functional analysis of A2780/CP cells following infection with ad5-SVV. As a result, knockdown of SVV downregulated the expression of PCNA and MMP-2 and upregulated the expression of pro-caspase-3 and cleaved caspase-3. In addition, knockdown of SVV enhanced cisplatin-induced proliferative activities, induced cell apoptosis and inhibited the invasive potential in A2780/CP cells. The present findings demonstrate that knockdown of SVV contributes to antitumor activity in cisplatin-resistant ovarian cancer cells via the downregulation of PCNA and MMP-2 expression and the upregulation of caspase-3 expression and indicate that SVV is a potential target for therapeutic anticancer drugs.

View Figures

View References

1	Eltabbakh G and Awtrey C: Current treatment for ovarian cancer. Expert Opin Pharmacother. 2:109–124. 2001. View Article : Google Scholar
2	McKeage M: New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs. 14:1033–1046. 2005. View Article : Google Scholar : PubMed/NCBI
3	Tewari K, Mehta R, Burger R, et al: Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 10:413–442. 2005. View Article : Google Scholar
4	Chen H, Hardy TM and Tollefsbol TO: Epigenomics of ovarian cancer and its chemoprevention. Front Genet. 2:672011. View Article : Google Scholar : PubMed/NCBI
5	Lee S, Choi E, Jin C, et al: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
6	Ferrandina G, Legge F, Martinelli E, et al: Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer. 92:271–277. 2005.
7	Liguang Z, Peishu L, Hongluan M, et al: Survivin expression in ovarian cancer. Exp Oncol. 29:121–125. 2007.PubMed/NCBI
8	No JH, Jeon YT, Kim YB, et al: Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. Gynecol Obstet Invest. 71:136–140. 2011. View Article : Google Scholar : PubMed/NCBI
9	Qian X, Xi X and Li L: Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol. 19:126–132. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kleinberg L, Flørenes VA, Silins I, et al: Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer. 109:228–238. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zaffaroni N, Pennati M, Colella G, et al: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
12	Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, et al: Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res. 4:202011. View Article : Google Scholar
13	Ma X, Wang S, Zhou J, et al: Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep. 14:275–279. 2005.PubMed/NCBI
14	Caldas H, Jaynes FO, Boyer MW, et al: Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther. 5:693–703. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhang B, Pan JS, Liu JY, et al: Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer. Methods Find Exp Clin Pharmacol. 28:619–625. 2006. View Article : Google Scholar : PubMed/NCBI
16	Zhang Z, Liao H, Chen X, et al: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol. 155:69–74. 2011. View Article : Google Scholar : PubMed/NCBI
17	Huang Y, Jin H, Liu Y, et al: FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocr Relat Cancer. 18:13–26. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tu CH, Liu WP, Dong M, et al: Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2. Mol Biol Rep. 38:2323–2328. 2011. View Article : Google Scholar : PubMed/NCBI
19	Roca H, Craig MJ, Ying C, et al: IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation. J Cell Biochem. 113:1569–1580. 2012.PubMed/NCBI
20	Xing J, Jia CR, Wang Y, et al: Effect of shRNA targeting survivin on ovarian cancer. J Cancer Res Clin Oncol. 138:1221–1229. 2012. View Article : Google Scholar : PubMed/NCBI
21	Nakahara T, Kita A, Yamanaka K, et al: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102:614–621. 2011. View Article : Google Scholar
22	Zheng F, Ruan F, Xie XK, et al: Apoptosis of drug-resistant human ovarian carcinoma cell line COC1/DDP induced by survivin antisense oligonucleotides. Chin Med J (Engl). 119:1572–1575. 2006.PubMed/NCBI
23	Zhang HY, Zhang PN and Sun H: Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol. 146:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
24	Weng D, Song X, Xing H, et al: Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett. 273:257–265. 2009. View Article : Google Scholar : PubMed/NCBI
25	Xing H, Weng D, Chen G, et al: Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 261:108–119. 2008. View Article : Google Scholar : PubMed/NCBI
26	Raj MH, Abd Elmageed ZY, Zhou J, et al: Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol. 110:432–438. 2008. View Article : Google Scholar : PubMed/NCBI
27	Azrak RG, Frank CL, Ghadersohi A, et al: Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells. Cancer Biol Ther. 7:1901–1908. 2008. View Article : Google Scholar : PubMed/NCBI
28	Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, et al: Silencing survivin splice variant 2B leads to antitumor activity in taxane - resistant ovarian cancer. Clin Cancer Res. 17:3716–3726. 2011. View Article : Google Scholar : PubMed/NCBI
29	Reitmaier M, Rudlowski C, Biesterfeld S, et al: Comparative studies on the biological significance of the marker for proliferation Ki-67-antigen and PCNA in primary ovarian carcinoma. Zentralbl Gynakol. 122:361–367. 2000.(In German).
30	Brinckerhoff CE, Rutter JL and Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 6:4823–4830. 2000.PubMed/NCBI
31	Flick MB, O’Malley D, Rutherford T, et al: Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig. 11:252–259. 2004. View Article : Google Scholar : PubMed/NCBI